Rhumbline Advisers boosted its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 1.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 392,355 shares of the biopharmaceutical company’s stock after buying an additional 5,479 shares during the period. Rhumbline Advisers’ holdings in Alexion Pharmaceuticals were worth $47,738,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of ALXN. Guardian Life Insurance Co. of America increased its stake in shares of Alexion Pharmaceuticals by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 6 shares during the period. Meeder Asset Management Inc. purchased a new stake in shares of Alexion Pharmaceuticals during the first quarter worth $111,000. Independent Portfolio Consultants Inc. increased its stake in shares of Alexion Pharmaceuticals by 46.9% in the first quarter. Independent Portfolio Consultants Inc. now owns 1,065 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 340 shares during the period. Huntington National Bank increased its stake in shares of Alexion Pharmaceuticals by 1,084.6% in the second quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock worth $131,000 after buying an additional 987 shares during the period. Finally, FUKOKU MUTUAL LIFE INSURANCE Co increased its stake in shares of Alexion Pharmaceuticals by 10.0% in the first quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 1,100 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 100 shares during the period. Institutional investors and hedge funds own 95.14% of the company’s stock.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) opened at 132.93 on Friday. Alexion Pharmaceuticals, Inc. has a one year low of $96.18 and a one year high of $145.42. The stock has a 50 day moving average price of $129.36 and a 200 day moving average price of $122.92. The firm has a market cap of $29.67 billion, a price-to-earnings ratio of 57.65 and a beta of 1.41.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, beating the Zacks’ consensus estimate of $1.08 by $0.48. The firm had revenue of $912 million for the quarter, compared to analyst estimates of $846.15 million. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The business’s quarterly revenue was up 21.1% compared to the same quarter last year. During the same period last year, the company earned $1.13 EPS. On average, equities research analysts forecast that Alexion Pharmaceuticals, Inc. will post $5.60 EPS for the current year.

WARNING: This piece was posted by Daily Political and is the property of of Daily Political. If you are reading this piece on another website, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece can be read at https://www.dailypolitical.com/2017/08/12/alexion-pharmaceuticals-inc-alxn-shares-bought-by-rhumbline-advisers.html.

A number of research analysts recently issued reports on the company. UBS AG restated a “buy” rating and set a $140.00 price objective (down previously from $143.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, May 31st. BMO Capital Markets restated an “outperform” rating and set a $158.00 price objective on shares of Alexion Pharmaceuticals in a research report on Monday, May 1st. SunTrust Banks, Inc. restated a “buy” rating and set a $165.00 price objective on shares of Alexion Pharmaceuticals in a research report on Friday, July 14th. Leerink Swann restated a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Tuesday, May 23rd. Finally, BidaskClub upgraded Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 5th. Five equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and three have issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $156.89.

In other news, CEO Ludwig Hantson acquired 10,000 shares of the firm’s stock in a transaction on Wednesday, June 14th. The shares were purchased at an average cost of $116.72 per share, for a total transaction of $1,167,200.00. Following the transaction, the chief executive officer now owns 38,725 shares of the company’s stock, valued at $4,519,982. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Ann M. Veneman sold 700 shares of the stock in a transaction on Monday, July 31st. The shares were sold at an average price of $137.74, for a total value of $96,418.00. Following the completion of the transaction, the director now owns 6,315 shares in the company, valued at $869,828.10. The disclosure for this sale can be found here. Insiders acquired a total of 2,019,734 shares of company stock worth $235,606,846 over the last quarter. Corporate insiders own 4.35% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.